Drug intelligence / Profile preview

azacitidine + valproic acid + carboplatin

Development stage: Discontinued
Lead developer: University of Texas MD Anderson Cancer Center
Modality: Small Molecules
Administration: Subcutaneous, Intravenous, Oral

Overview

A combination regimen consisting of azacitidine, valproic acid, and carboplatin. This therapeutic approach, investigated by the M.D. Anderson Cancer Center, aims to treat platinum-resistant epithelial ovarian cancer. The strategy utilizes azacitidine (a DNA methyltransferase inhibitor) and valproic acid (a histone deacetylase inhibitor) as epigenetic priming agents to sensitize tumor cells to the cytotoxic effects of carboplatin (a platinum-based DNA alkylating agent). By reversing DNA methylation and histone deacetylation, the combination seeks to restore the expression of genes involved in apoptosis and platinum sensitivity, potentially overcoming resistance mechanisms in advanced solid tumors.

Other names: Azacitidine, Valproic Acid, and Carboplatin

Targets

DNMT1 (DNA (cytosine-5)-methyltransferase 1)HDAC (HDAC family)DNA

Beyond the preview

Go deeper on azacitidine + valproic acid + carboplatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on azacitidine + valproic acid + carboplatin.

Explore the full profile